Bioavailability Investigations of Thyronajod Mite Tablets of Dosage Strengths 50 μg Levothyrox-ine/75 μg Iodine, and 100 μg Levothyroxine/75 μg Iodine vs. a Levothyroxine Drinking-Solution: A Randomised Cross Over Study in Healthy Male Individuals. Currently: 50 μg/ 75 μg Tablets
Launched by HEIDELBERG UNIVERSITY · Nov 4, 2011
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Euthyroid men
- • Age: 18 - 50
- • Normal values for fT4 und TSH
- • Good state of health
- Exclusion Criteria:
- • Thyroid function disorders in terms of subclinical or overt hyper- or hypothyroidism
- • History of thyroid function disorders
- • Focal or diffuse autonomies of the thyroid gland
- • Thyroid nodules \>1 ml according to sonographic examination
- • Any acute or chronic illness
- • Dermatitis herpetiformis
About Heidelberg University
Heidelberg University, a prestigious institution located in Germany, is renowned for its commitment to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university fosters a dynamic environment for conducting clinical trials that aim to enhance patient care and improve health outcomes. Leveraging cutting-edge technology and a robust network of healthcare professionals, Heidelberg University is dedicated to exploring novel therapeutic approaches and contributing to the global medical community through rigorous scientific inquiry and ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials